Millions of Samsung Galaxy Phones May Be Vulnerable to Hackers
If you’re one of the millions of users of a Samsung Galaxy phone, you might be a potential target for a malicious hacker.
A report released today by NowSecure, a security firm located in Chicago, found that a glitch in Swift, the keyboard software used by default on all Samsung Galaxy devices could allow a remote attacker to compromise your phone.
This particular bug makes the phone vulnerable to what is known as a “man in the middle” attack. The Swift software consistently sends requests to a server, checking for updates. To someone with the right knowhow, though, it’s possible to impersonate Swift’s server and send through software that can be used to gain control of the device.
The main problem with this vulnerability is that there’s no real solution. The Swift keyboard is so integrated into Samsung’s software that it cannot be removed or disabled — even if it is switched out with a different keyboard app. Steering clear of unsecured Wi-Fi networks will make you less likely to be targeted, but it won’t render you invulnerable.
Related: 10 Biggest Tech Flops of the Century
Swift runs with elevated permissions, giving it pretty much free rein around the phone. This means that a hacker that worms his way into it can also access the Galaxy’s microphone and camera, track the user’s location or listen to their calls. They can even install apps.
NowSecure claims to have made Samsung and Google’s Android team aware of this vulnerability in late 2014, and Samsung reportedly has made a patch available to network providers. It’s not clear, though, whether providers have pushed out the patch to users yet. Many networks have a record of being notoriously slow to push through updates and security patches, and NowSecure’s tests found a number of Galaxy phones on different carriers were still vulnerable as of Tuesday.
If you’re of a more technical bent, you may be interested in seeing the details of NowSecure’s report on their blog. If you’re of a less technical bent, you might want to check with your carrier and try to avoid insecure Wi-Fi networks.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.